In short
There is currently 1 ongoing clinical trial for chronic glomerulonephritis, specifically focusing on ANCA-associated vasculitis, a condition that causes inflammation of blood vessels and can affect the kidneys. The trial is investigating the use of rituximab, a medication that helps manage this condition, and is comparing the outcomes of patients who continue taking it versus those who stop.
Clinical trial locations
Study on Stopping Rituximab vs. Continuing Rituximab for Patients with ANCA-Associated Vasculitis in Stable Remission
This clinical trial is being conducted in Sweden and focuses on a condition called ANCA-associated vasculitis, which causes inflammation in small blood vessels. This inflammation can affect various organs, including the kidneys, lungs, and skin. The study is specifically looking at patients who have been in stable remission, meaning their symptoms have been under control for some time.
Main inclusion criteria:
- Patients must have a confirmed diagnosis of ANCA-associated vasculitis, including types such as granulomatosis with polyangiitis or microscopic polyangiitis
- They must have a current or previous positive test for specific antibodies called PR3/MPO-ANCA
- Patients must have been in stable remission for at least 24 months
- They must have completed at least 24 months of rituximab maintenance therapy, with the last dose given at least 6 months before joining the study
- Women who can become pregnant must use effective birth control during treatment and for 12 months after stopping rituximab, and must have a negative pregnancy test at the start of the study
Main exclusion criteria:
- Patients whose condition is not currently under control or in stable remission
- Patients who have not been previously treated with rituximab
- Patients who belong to vulnerable populations that may require special protection
- Patients outside the specified age range for the study
Focus and goal of the trial:
The primary purpose of this study is to compare what happens when patients either continue taking rituximab or stop taking it after achieving stable remission. Participants will be randomly assigned to one of two groups: those who will discontinue rituximab treatment and those who will continue with regular maintenance therapy. The main goal is to see which approach results in a lower rate of disease relapse, meaning a return of symptoms.
The study will monitor participants over an extended period, tracking several important outcomes. These include how long it takes for the disease to relapse, whether remission is maintained at 24 and 36 months, changes in antibody levels, kidney function, and overall quality of life. Regular assessments will be conducted throughout the trial to evaluate these factors. The study is expected to conclude by December 31, 2029.
Investigational drug:
Rituximab is the medication being studied in this trial. It is administered through an intravenous drip, meaning it is given directly into a vein. The dosage used is either 500 mg or 1000 mg, depending on the patient's previous treatment history. Rituximab works by targeting and reducing specific immune cells called CD20-positive B cells, which play a role in causing the inflammation seen in ANCA-associated vasculitis. This medication is already well-established in medical practice for treating this condition and other autoimmune diseases.
Summary
Currently, there is one clinical trial available for patients with chronic glomerulonephritis related to ANCA-associated vasculitis. The trial is taking place in Sweden and is focused on understanding the best long-term management strategy for patients who have achieved stable remission with rituximab therapy. The study aims to provide valuable insights into whether continuing or stopping rituximab after extended remission leads to better outcomes for patients, potentially improving treatment guidelines for this rare but serious condition in the future.
